How do patients fare when they have cancer and COVID-19? Researchers developed the COVID-19 and Cancer Consortium (CCC19) and the National Cancer Institute COVID-19 in Cancer Patients Study (NCCAPS) to gain some insight.
In this episode, Brian Rini, MD, a professor of medicine at Vanderbilt University Medical Center, Nashville, Tenn., and host of The Uromigos podcast, explains what CCC19 and NCCAPS are. He also discusses findings f...
This week in Hematology and Oncology news:
* * *
Find more Blood & Cancer at htt...
How has COVID-19 impacted medical students? Two students from Royal College of Surgeons in Ireland (RCSI), Dublin, describe their experiences in this episode.
Evani Patel and Sarah Chen, both second-year medical students at RCSI, tell host David H. Henry, MD, how the COVID-19 pandemic has shaped their educational experience thus far.
Now, the pandemic has shifted the students’ education to a mix of virtual and in-person learning at...
Pralsetinib: Second drug for RET+ NSCLC approved in U.S.: https://bit.ly/3bTdGaz
Treatment strategies for myelodysplastic syndromes (MDS) vary widely depending upon patients’ prognosis. In this episode, Shannon R. McCurdy, MD, of the University of Pennsylvania, Philadelphia, joined host David H. Henry, MD, to discuss how she treats patients with MDS.
Episode 94 features the best of ASCO 2020, and we'll see you all with new content for episodes 95 and 96.
* * *
MDedge Hematology-Oncology news for the first week of September 2020.
The SECURE-SCD registry was designed to collect and disseminate information on patients with sickle cell disease (SCD) who develop COVID-19.
In this episode, Dr. Brandow and Dr. Panepinto discuss SECURE-SCD and its findings with host David H. Henry, MD.
News for the week of August 24, 2020.
Dr. David Henry welcomes NBA power forward Mason Plumlee. Plumlee, who is now participating in the NBA's controlled COVID-19 environment, affectionately referred to as the "bubble," tested positive for COVID-19 before we knew that loss of taste and smell was a symptom.
In a wellness and intellectual change-of-pace episode, Plumlee joins Dr. Henry to talk about his background in medicine and biology, his experiences in ...
Hanny Al-Samkari, MD, joins the podcast to discuss thrombosis in COVID-19 and lung cancer patients as well as the use of bevacizumab in patients with hereditary hemorrhagic telangiectasia (HHT).
Dr. Al-Samkari, of Massachusetts General Hospital, presented three studies on these topics at the virtual ISTH 2020 Congress. In this episode, Dr. Al-Samkari describes these studies to host David H. Henry, MD.
This week in HemOnc news:
How does the community oncologist treat multiple myeloma? Gustavo A. Fonseca, MD, of Florida Cancer Specialists, shares his approach to myeloma treatment with host David H. Henry, MD.
The pair then move on to discuss hypothetical myeloma cases and advances in treatme...
This week in HemOnc News:
Large cohort study: Bevacizumab safe, effective for severe HHT bleeds
COVID-19 can have a negative impact on systems throughout the body, beyond just the lungs, according to a review published in Nature Medicine. Two authors of the review joined host David H. Henry, MD, to discuss their article, “Extrapulmonary manifestations of COVID-19.”
This week in HemOnc News:
While relaxing on the Jersey Shore, host and MDedge Hematology/Oncology Editor-in-Chief, David Henry, MD, dove into the July 10, 2020, issue of the Journal of Clinical Oncology. In episode 82, we do the same.
J Clin Oncol. 2020 Jul 10. 38(20). 2217-2361. (https://bit.ly/2ZQEJ27)
You can follow along with the following articles:
The latest news from MDedge Hematology/Oncology:
In this episode: